266 related articles for article (PubMed ID: 24312298)
1. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
[TBL] [Abstract][Full Text] [Related]
2. Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.
Fischer DL; Manfredsson FP; Kemp CJ; Cole-Strauss A; Lipton JW; Duffy MF; Polinski NK; Steece-Collier K; Collier TJ; Gombash SE; Buhlinger DJ; Sortwell CE
Sci Rep; 2017 Nov; 7(1):16356. PubMed ID: 29180681
[TBL] [Abstract][Full Text] [Related]
3. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
4. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
[TBL] [Abstract][Full Text] [Related]
5. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
[TBL] [Abstract][Full Text] [Related]
6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.
Gombash SE; Manfredsson FP; Mandel RJ; Collier TJ; Fischer DL; Kemp CJ; Kuhn NM; Wohlgenant SL; Fleming SM; Sortwell CE
Gene Ther; 2014 Jul; 21(7):682-93. PubMed ID: 24807806
[TBL] [Abstract][Full Text] [Related]
9. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
Khodr CE; Becerra A; Han Y; Bohn MC
Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
[TBL] [Abstract][Full Text] [Related]
10. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
[TBL] [Abstract][Full Text] [Related]
11. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
12. AAV2/DJ-mediated alpha-synuclein overexpression in the rat substantia nigra as early stage model of Parkinson's disease.
von Hövel FF; Rumpel R; Ratzka A; Schreiner D; Grothe C
Cell Tissue Res; 2019 Oct; 378(1):1-14. PubMed ID: 30989398
[TBL] [Abstract][Full Text] [Related]
13. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
[TBL] [Abstract][Full Text] [Related]
14. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
[TBL] [Abstract][Full Text] [Related]
15. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
[TBL] [Abstract][Full Text] [Related]
16. Ciita Regulates Local and Systemic Immune Responses in a Combined rAAV-α-synuclein and Preformed Fibril-Induced Rat Model for Parkinson's Disease.
Fredlund F; Jimenez-Ferrer I; Grabert K; Belfiori LF; Luk K; Swanberg M
J Parkinsons Dis; 2024; 14(4):693-711. PubMed ID: 38728204
[TBL] [Abstract][Full Text] [Related]
17. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
18. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease.
Manfredsson FP; Burger C; Sullivan LF; Muzyczka N; Lewin AS; Mandel RJ
Exp Neurol; 2007 Oct; 207(2):289-301. PubMed ID: 17678648
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors.
Hall H; Jewett M; Landeck N; Nilsson N; Schagerlöf U; Leanza G; Kirik D
PLoS One; 2013; 8(5):e64844. PubMed ID: 23705016
[TBL] [Abstract][Full Text] [Related]
20. DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease.
Arkan S; Ljungberg M; Kirik D; Hansen C
Neurobiol Dis; 2021 Oct; 158():105477. PubMed ID: 34390836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
